探讨黄芪注射液在小儿支原体肺炎中的疗效及安全性  

Investigation on efficacy and safety of astragalus injection in the treatment of mycoplasma pneumonia in children

作　　者：司凯英[1] 姚晓颖[1] 刘志宝[1] 孙继红 SI Kai-ying;YAO Xiao-ying;LIU Zhi-bao(Daqing Oilfield General Hospital, Daqing 163000,China)

机构地区：[1]大庆油田总医院,163000 [2]黑龙江省海员总医院

出　　处：《中国现代药物应用》2017年第15期84-85,共2页Chinese Journal of Modern Drug Application

摘　　要：目的探讨分析小儿支原体肺炎使用黄芪注射液治疗的临床效果和安全性。方法 68例小儿支原体肺炎患儿,随机分为对照组和实验组,各34例。对照组患儿接受常规西药治疗,实验组患儿接受西药治疗和黄芪注射液治疗,比较分析两组的临床疗效以及并发症情况。结果实验组治疗总有效率为97.1%、并发症发生率为5.9%,对照组治疗总有效率为82.4%、并发症发生率为23.5%,实验组治疗总有效率高于对照组、并发症发生率低于对照组,差异具有统计学意义(P<0.05)。结论黄芪注射液治疗小儿支原体肺炎的临床效果突出,临床安全较高,值得推广使用。Objective To investigate the clinical effect and safety of astragalus injection in the treatmentof mycoplasma pneumonia in children.Methods A total of68children with mycoplasma pneumonia randomlydivided into control group and experimental group,with34cases in each group.The control group was treatedwith conventional western medicine,and the experimental group was treated with western medicine and astragalusinjection.Comparison and analysis were made on clinical efficacy and complications in two groups.Results Theexperimental group had total treatment effective rate as97.1%and incidence of complications as5.9%,while thecontrol group had total treatment effective rate as82.4%and incidence of complications as23.5%.The experimentalgroup had higher total effective rate than the control group and lower incidence of complications than the controlgroup.Their difference had statistical significance(P<0.05).Conclusion Astragalus injection shows remarkableclinical effect in treating mycoplasma pneumonia in children with high clinical safety,and it is worth promotion.

关 键 词：黄芪注射液 支原体肺炎 疗效 安全性 

分 类 号：R272[医药卫生—中医儿科学]